OncoDNA anticipates a strong increase in the use of OncoDNA profiling products in Europe with the partnerships with Gammaray and AMS.
The company also published a study describing ImmRay PanCan-D biomarker signature that it said could be used to detect early-stage pancreatic cancer.
KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
The researchers distinguished histologic subtypes of appendiceal cancer and confirmed that it is distinct from colorectal and other GI cancers.
PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
Penn bioinformaticians are testing REALGAR, an application to simplify searches of GWAS, WGS, RNA-seq, and other test results for wet-lab researchers.
The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.
The companies will use Ymir's urine extracellular vesicle technology and OHSU's Proteomics Shared Resource to develop biomarkers for hepatocellular carcinoma.
The firm hopes its newly launched DxWound will improve pathogen detection in skin and soft tissue infections by including anaerobic and fungal microbes in its reports.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.